Clinical Trials Logo

Clinical Trial Summary

Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head & neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. All patients will undergo Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computerized Tomography (PET-CT) prior to examination in general anesthesia. During general anesthesia, Intraoperative Transoral Ultrasound (ITUS) will be performed prior to panendoscopy. Detected tumors will be registered with specified oropharyngeal sub-locations. Blinded to ITUS, a consultant head & neck surgeon will perform panendoscopy. After examination, the surgeon is unblinded to ultrasound results. Final histopathology results from location-specified biopsies performed will be used as reference standard. The overall detection rate will be compared between ITUS, panendoscopy, PET-CT and MRI with sensitivity and specificity analysis. Oropharynx sub-location specific detection rate of ITUS vs. panendoscopy will be compared with logistic regression analysis.


Clinical Trial Description

A prospective diagnostic study examining patients with suspected SCCUP will be performed at the Department of Otorhinolaryngology & Head & Neck Surgery, Copenhagen University Hospital - Rigshospitalet, Denmark. This specialized cancer center is responsible for the surgical work-up for approximately half of suspected SCCUP patients in the Danish population of 5.8 million. Standard work-up of patients with suspected SCCUP in Denmark consists of same-day clinical examination combined with high resolution video endoscopy with NBI, surgeon-performed neck ultrasound and fine-needle aspiration cytology (FNAC) of suspected lymph nodes with same-day results. Cytology results can be further tested for Human Papillomavirus (HPV), and patients are booked for panendoscopic examination under general anesthesia with frozen section biopsy. Pre-operative cross-sectional imaging to locate the primary tumor includes MRI and 18-F Fluordeoxyglucose (FDG) PET-CT. Intraoperative transoral ultrasound During general anesthesia and prior to panendoscopy, ITUS will be performed while a consultant head & neck surgeon performing panendoscopy is blinded. A Fujifilm Arietta 850 or Arietta 65 (Fujifilm, Tokyo, Japan), BK5000 (BK Medical ApS, Herlev, Denmark), or Samsung RS85 (Samsung Medison, Seoul, South Korea) ultrasound machines will be used. Small-footprint, high-frequency transducers such as the Arietta L51K linear-array intraoperative robot transducer attached to a forceps, the BK5000 "flexible hockey-stick" 18XL5s, or the Samsung RS85 LA3-22AI "hockeystick" will be used. A Boyle-Davis gag or laryngoscope will be used to visualize the tonsils (Figure 1), while the transducer is placed onto each tonsil in transverse and sagittal planes. The tongue base will be scanned by pulling the tongue anteriorly by an assistant and placing the transducer directly onto the tongue base. Alternatively, the tongue can be retracted with a video-laryngoscope while revealing the tongue base. The tongue base will be scanned from side to side in the sagittal plane. The tongue can then be pulled to either the left or right side to angle the probe obliquely for transverse imaging. If a tumor is suspected, the tumor location is registered in the following categories, including indication of right or left side: - Tonsil cranial. - Tonsil caudal. - Glossotonsillar sulcus. - Anterolateral tongue base. - Anteromedial tongue base. - Posterolateral tongue base. - Posteromedial tongue base. - "Other" oropharynx sub-locations, including anterior & posterior pharyngeal arches, soft palate, uvula, posterior oropharynx wall, and vallecula. B-mode video clips of both tonsils and the tongue base will be recorded. Power doppler for suspected tumors and the contralateral side will be performed. If a well-defined lesion is seen, the greatest tumor diameter and if possible, three-dimensional size is measured. The grade of tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high). Panendoscopy Following ITUS, the surgeon will perform standard panendoscopy of the pharynx including palpation of the oral cavity and oropharynx, and high-resolution video endoscopy with NBI. If the surgeon suspects a tumor, the location is registered with the same categories as above. Tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high). The surgeon will categorize visual findings such as ulcers, exophytic tumors, asymmetric tissue, vulnerable/bleeding mucosa, suspect vasculature on NBI, or no suspect visual findings. The surgeon will categorize palpatory findings as soft or firm. The clinically visualized or palpated greatest tumor diameter will be estimated. The surgeon is then unblinded to ultrasound results. After unblinding from ultrasound, the investigators will register whether further directed biopsies from ultrasound suspected location are performed. If the primary tumor is not located during panendoscopy, patients will tonsillectomied and the tonsils will be sliced in 2mm slices by head & neck pathologists in search of the primary tumor. If the primary tumor is still unknown and the neck metastasis is HPV+, then patients are offered Transoral Robotic Surgery (TORS) with diagnostic tongue base mucosectomy. These tongue base specimens will also be sliced in 2mm slices and examined by head & neck pathologists. If the primary tumor is located in final histopathology from either tonsillectomies or tongue base mucosectomy, the location of the tumors will be compared to the initially registered suspected ultrasound locations from panendoscopy. Medical chart data The patient's age, sex, alcohol, smoking, largest cervical lymph node size, cervical lymph node side (right/left), date of panendoscopy, date of conclusive histopathology results, and date of treatment initiation will be obtained from medical charts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05841966
Study type Interventional
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase N/A
Start date February 21, 2023
Completion date March 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT03278600 - Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary Phase 3
Recruiting NCT04504604 - TCF-001 TRACK (Target Rare Cancer Knowledge) Study N/A
Completed NCT03053466 - APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Phase 1
Active, not recruiting NCT04750109 - Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Recruiting NCT04952103 - Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Recruiting NCT04969835 - A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Phase 1
Active, not recruiting NCT03498521 - A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Phase 2
Completed NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2
Recruiting NCT05263700 - FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary N/A
Active, not recruiting NCT03752333 - Trial of Pembrolizumab in Cancer of Unknown Primary Phase 2
Recruiting NCT04131621 - Nivolumab/Ipilimumab in Second Line CUP-syndrome Phase 2
Recruiting NCT04459273 - Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers Phase 1
Active, not recruiting NCT05024968 - Sintilimab in Cancer of Unknown Primary Phase 2